Fulgent Genetics Inc (FLGT) - Total Assets
Based on the latest financial reports, Fulgent Genetics Inc (FLGT) holds total assets worth $1.16 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Fulgent Genetics Inc to assess the company's total reinvestment commitment from operating cash flow.
Fulgent Genetics Inc - Total Assets Trend (2014–2025)
This chart illustrates how Fulgent Genetics Inc's total assets have evolved over time, based on quarterly financial data. Explore Fulgent Genetics Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Fulgent Genetics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Fulgent Genetics Inc's total assets of $1.16 Billion consist of 45.4% current assets and 54.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.1% |
| Accounts Receivable | $91.61 Million | 7.6% |
| Inventory | $10.60 Million | 0.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $133.28 Million | 11.0% |
| Goodwill | $25.08 Million | 2.1% |
Asset Composition Trend (2014–2025)
This chart illustrates how Fulgent Genetics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Fulgent Genetics Inc (FLGT) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fulgent Genetics Inc's current assets represent 45.4% of total assets in 2025, an increase from 33.5% in 2014.
- Cash Position: Cash and equivalents constituted 4.1% of total assets in 2025, down from 8.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 11.0% of total assets.
Fulgent Genetics Inc Competitors by Total Assets
Key competitors of Fulgent Genetics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.33 Billion |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716
|
China | CN¥1.74 Billion |
|
Spectral Med Inc
TO:EDT
|
Canada | CA$8.12 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Genetic Signatures Ltd
AU:GSS
|
Australia | AU$49.04 Million |
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
Germany | €13.12 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
Fulgent Genetics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.31 | 6.32 | 4.66 |
| Quick Ratio | 5.31 | 6.19 | 4.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $388.91 Million | $350.87 Million | $445.16 Million |
Fulgent Genetics Inc - Advanced Valuation Insights
This section examines the relationship between Fulgent Genetics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.51 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | -0.5% |
| Total Assets | $1.21 Billion |
| Market Capitalization | $511.21 Million USD |
Valuation Analysis
Below Book Valuation: The market values Fulgent Genetics Inc's assets below their book value (0.42x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Fulgent Genetics Inc's assets decreased by 0.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Fulgent Genetics Inc (2014–2025)
The table below shows the annual total assets of Fulgent Genetics Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.21 Billion | -0.53% |
| 2024-12-31 | $1.22 Billion | -1.24% |
| 2023-12-31 | $1.24 Billion | -10.87% |
| 2022-12-31 | $1.39 Billion | +8.39% |
| 2021-12-31 | $1.28 Billion | +82.55% |
| 2020-12-31 | $700.46 Million | +689.20% |
| 2019-12-31 | $88.76 Million | +61.33% |
| 2018-12-31 | $55.02 Million | -3.40% |
| 2017-12-31 | $56.95 Million | -1.88% |
| 2016-12-31 | $58.04 Million | +895.20% |
| 2015-12-31 | $5.83 Million | +175.09% |
| 2014-12-31 | $2.12 Million | -- |
About Fulgent Genetics Inc
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pa… Read more